DexCom (DXCM) Downgraded by ValuEngine

ValuEngine cut shares of DexCom (NASDAQ:DXCM) from a hold rating to a sell rating in a research report released on Thursday.

DXCM has been the subject of a number of other reports. TheStreet downgraded DexCom from a c- rating to a d+ rating in a research note on Wednesday, October 25th. BidaskClub downgraded DexCom from a strong-buy rating to a buy rating in a research note on Friday, December 22nd. Morgan Stanley decreased their price target on DexCom from $72.00 to $52.00 and set a neutral rating for the company in a research note on Friday, November 3rd. Zacks Investment Research downgraded DexCom from a hold rating to a sell rating in a research note on Tuesday, October 17th. Finally, Jefferies Group raised their price target on DexCom from $58.00 to $70.00 and gave the company a buy rating in a research note on Friday, December 22nd. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating and fourteen have issued a buy rating to the company. The stock currently has an average rating of Hold and an average target price of $68.50.

DexCom (DXCM) opened at $54.35 on Thursday. The company has a quick ratio of 5.50, a current ratio of 5.86 and a debt-to-equity ratio of 0.84. DexCom has a one year low of $42.62 and a one year high of $86.32.

In other news, Director Barbara Kahn sold 3,000 shares of DexCom stock in a transaction that occurred on Monday, November 20th. The stock was sold at an average price of $54.58, for a total transaction of $163,740.00. Following the completion of the transaction, the director now directly owns 4,353 shares in the company, valued at approximately $237,586.74. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Kevin R. Sayer sold 12,000 shares of DexCom stock in a transaction that occurred on Monday, November 20th. The stock was sold at an average price of $55.00, for a total value of $660,000.00. The disclosure for this sale can be found here. Insiders have sold a total of 48,140 shares of company stock valued at $2,743,281 over the last quarter. 1.70% of the stock is currently owned by corporate insiders.

Several hedge funds and other institutional investors have recently modified their holdings of the company. FDx Advisors Inc. boosted its stake in shares of DexCom by 33.3% during the 4th quarter. FDx Advisors Inc. now owns 23,071 shares of the medical device company’s stock worth $1,324,000 after acquiring an additional 5,764 shares during the period. American International Group Inc. acquired a new stake in DexCom during the 4th quarter worth approximately $116,000. Wedbush Securities Inc. lifted its holdings in DexCom by 24.2% during the 4th quarter. Wedbush Securities Inc. now owns 5,589 shares of the medical device company’s stock worth $321,000 after purchasing an additional 1,089 shares during the last quarter. Capital Fund Management S.A. acquired a new stake in DexCom during the 4th quarter worth approximately $5,013,000. Finally, D.A. Davidson & CO. acquired a new stake in DexCom during the 4th quarter worth approximately $208,000.

COPYRIGHT VIOLATION WARNING: This article was first posted by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://stocknewstimes.com/2018/02/11/dexcom-dxcm-downgraded-by-valuengine.html.

DexCom Company Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply